Therefore, the dosage of systemic IL-2 administration in these studies may play an important role in promoting the T cell response against the tumor, since low dose IL-2 has been used to preferentially expand Treg cells to attenuate the progression of human autoimmune diseases (222, 223). The gene discussed is IL2; the disease is autoimmune disease.